Abstract
Seventy-one mobilised PBSC collections were subject to CD34+ cell purification using the CEPRATE SC® stem cell concentration system. The overall median purity of CD34+ cells was 69% (6–93%). CD34+ cell, and GM-CFC recoveries were 52% (8–107%) and 36% (3–118%). Purity was logarithmically related to the input percentage of CD34+ cells and starting requirements were established of 1% CD34 cell content for optimal purity and a minimum of 2 × 106/kg CD34+ cells to ensure recovery of our minimum engraftment threshold of 1 × 106/kg CD34+ cells. Reduction of the washing steps reduced non-specific cell losses and shortened the procedure but did not affect progenitor cell recovery. Purified CD34+ cells were reinfused following high-dose therapy in 35 patients. The median time to neutrophil recovery of 0.5 × 109/l was 12 (10–23) days and to the attainment of platelet independence was 13 (7–100) days. The risks of delayed platelet recovery were related to the CD34+ cell dose infused and were identical to the risks when non-purified PBSC collections were used. In conclusion, purification of CD34+ cells using the CEPRATE device is reliable and the purified product results in prompt engraftment. The cell losses that occur do however restrict its use in many patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Watts, M., Sullivan, A., Ings, S. et al. Evaluation of clinical scale CD34+ cell purification: experience of 71 immunoaffinity column procedures. Bone Marrow Transplant 20, 157–162 (1997). https://doi.org/10.1038/sj.bmt.1700879
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1700879
Keywords
This article is cited by
-
ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF
Bone Marrow Transplantation (2005)
-
Large-scale mobilization and isolation of CD34+ cells from normal donors
Bone Marrow Transplantation (2000)
-
Transplantation of highly purified HLA-identical sibling donor peripheral blood CD34+ cells without prophylactic post-transplant immunosuppression in adult patients with first chronic phase chronic myeloid leukemia: results of a phase II study
Bone Marrow Transplantation (2000)